Vital Signsby BridgeheadAll voices

01  Voice · Clinician · Dementia

Clinician

Professor Ramin Nilforooshan

Consultant Psychiatrist (Older People's Mental Health) and Director of Research and Development; Visiting Professor, University of Surrey, Surrey and Borders Partnership NHS Foundation Trust

Press coverage by month · bar height shows relative volume
Sept 2026Oct 2026Nov 2026to date
Also cited

Quoted in the press on 1 topic since 4 Sept 2026

Where their coverage sitsTop 20–50%

Voices are sorted into four fixed groups by how much press coverage they have had across all topics, from the top 5% down to the lower half. The lit step is Professor Ramin Nilforooshan’s group.

LEATHERHEAD
OfficeSurrey and Borders Partnership NHS Foundation Trust, Leatherhead, KT22 7ADSurrey and Borders Partnership NHS Foundation Trust is based in Epsom and Ewell (Leatherhead): the organisation’s base, not a personal address.

02  Quoted on · 1 of 29 topics

Open the topic

Professor Ramin Nilforooshan: key facts

Kind of voice
Clinician
Role
Consultant Psychiatrist (Older People's Mental Health) and Director of Research and Development; Visiting Professor, University of Surrey
Organisation
Surrey and Borders Partnership NHS Foundation Trust
Organisation based in
Epsom and Ewell
Quoted on
Dementia
Press coverage
Also cited
Most recently quoted
20 Sept 2026
First quoted
4 Sept 2026

03  Profile

Who Professor Ramin Nilforooshan is

<cite index="1-2">Professor Ramin Nilforooshan is a professor in psychiatry at the University of Surrey and a consultant psychiatrist for older adults at Surrey and Borders Partnership NHS Foundation Trust (SABP).</cite> <cite index="1-3">He is the trust's director of R&D and the Dementia Speciality Lead for the Clinical Research Network in Kent, Surrey and Sussex.</cite> <cite index="8-2,8-3">He trained in psychiatry on the Guy's and Maudsley rotation and has been a consultant psychiatrist for older adults at SABP since 2011.</cite> <cite index="4-2">He is Chief Investigator for PrevenTRON</cite>, <cite index="10-3,10-4">a phase III study of whether the drug trontinemab can delay or prevent Alzheimer's in people at high risk, before memory and thinking problems begin.</cite> <cite index="31-3">He is also clinical lead for the Internet of Things NHS Test Bed Technology Integrated Health Management (TIHM) for dementia.</cite> In press coverage he argues for acting on Alzheimer's earlier, <cite index="10-7">saying PrevenTRON asks whether we can act earlier, before symptoms begin.</cite>

Notable achievements

  1. 01

    Chief Investigator for the PrevenTRON phase III Alzheimer's prevention trial. SABP became the first site in the UK and Europe, and the third in the world, to offer the drug. Source ↗

  2. 02

    Clinical lead for TIHM for dementia. The study, led by the University of Surrey and SABP, won the 'Improving Care with Technology' award at the HSJ Awards. Source ↗

  3. 03

    Chief Investigator for the Minder study. SABP's TIHM work and its collaboration with the UK DRI on Minder underpin the MinderCare home-monitoring service for dementia. Source ↗

Research & publications

Publication records from OpenAlex and Europe PMC, matched on name and affiliation. Every entry links to its DOI so the attribution can be checked.

04  The signal · where Professor Ramin Nilforooshan sits on dementia

Leading

One of the voices most often quoted in the press on dementia.

Placed by press coverage on this topic only, not across all topics.

  1. Lesley PotterClinicianAdmiral Nurse, Dementia UKLeading
  2. Dr Sheona Scales portraitDr Sheona ScalesSector leaderDirector of Research, Alzheimer's Research UKLeading
  3. Dr Richard Oakley portraitDr Richard OakleySector leaderAssociate Director of Research and Innovation, Alzheimer's SocietyLeading
  4. Dr Jacqui HanleySector leaderHead of Research Funding, Alzheimer's Research UKLeading
  5. Dr. Josef Coresh portraitDr. Josef CoreshAcademicFounding Director, Optimal Aging Institute; Terry and Mel Karmazin Professor of Population Health; Professor of Medicine, NYU Grossman School of Medicine / NYU Langone HealthLeading
  6. Professor Ramin Nilforooshan portraitProfessor Ramin NilforooshanClinicianConsultant Psychiatrist (Older People's Mental Health) and Director of Research and Development; Visiting Professor, University of Surrey, Surrey and Borders Partnership NHS Foundation TrustLeading
  7. Dr Hilda HayoClinicianChief Admiral Nurse and CEO of Dementia UKLeading
  8. Professor Siddharthan ChandranAcademicdirector and CEO, UK Dementia Research Institute; practising neurologistLeading

Showing the leading voices and those placed around Professor Ramin Nilforooshan · See every voice on the topic →

05  On the record · press

What Professor Ramin Nilforooshan has said

By outlet · bar length shows relative volume
  • aol.co.uk
  • express.co.uk
  • bbc.co.uk
  • independent.co.uk
  • inews.co.uk

Where Professor Ramin Nilforooshan has been quoted

  1. The drugs that could slow Alzheimer's - and when they could come to NHSinews.co.uk · 20 Sept 2026
  2. Surrey and Borders Leads European Alzheimer’s Prevention Trialthecareruk.com · 7 Sept 2026
  3. Major trial of Roche Alzheimer's drug kicks off in Europepharmaphorum.com · 7 Sept 2026
  4. People without memory loss symptoms to join trial testing drug to prevent Alzheimer's | LBClbc.co.uk · 6 Sept 2026
  5. ‘Dementia drug’ to be offered to over 55s in UKexpress.co.uk · 5 Sept 2026
  6. NHS trust joins Alzheimer's prevention drug trialbbc.co.uk · 5 Sept 2026
  7. Alzheimer's drug to be offered to people without symptoms to stop it developingmirror.co.uk · 5 Sept 2026
  8. Alzheimer’s trial to test drug on people without symptoms to see if it can be preventedtheguardian.com · 5 Sept 2026
  9. Alzheimer's drug to be offered to people without symptoms to stop it developing - AOLaol.co.uk · 5 Sept 2026
  10. Alzheimer's drug to be offered to people without symptoms in bid to prevent onsetindependent.co.uk · 5 Sept 2026
  11. Alzheimer's trial to test drug on people without symptoms to see if it can be prevented - AOLaol.co.uk · 5 Sept 2026
  12. 'Dementia drug' to be offered to over 55s in UK - AOLaol.co.uk · 5 Sept 2026
  13. Healthy middle-aged people offered Alzheimer’s drug in world-first trialtelegraph.co.uk · 4 Sept 2026
  14. British patients 'first to trial next-generation dementia drug' from next week - AOLaol.co.uk · 4 Sept 2026
  15. British patients 'first to trial next-generation dementia drug' from next weekexpress.co.uk · 4 Sept 2026
  16. NHS trust joins Alzheimer’s prevention trialyahoo.com

How we found the articles that name Professor Ramin Nilforooshan: we searched news for these terms.

  • dementia
  • dementia care
  • Alzheimer's
  • memory clinic
  • dementia diagnosis
  • dementia strategy

Also searched with “dementia” in each of 8 national papers, and in the Guardian by editor tag, and in trade press by category. Every term for Dementia

Verbatim

“The brain shuttle is way faster and has less side effects.”
Professor, psychiatrist at the University of Surrey · Dementia · inews.co.uk · 20 Sept 2026 · Read the article
“Being the first site across Europe and the third in the world to open PrevenTRON is a proud moment for our Research and Development team and for the communities we serve. For decades, research has focused on treating Alzheimer's disease after symptoms appear. PrevenTRON addresses a different question, whether we can act earlier, before symptoms begin.”
Consultant psychiatrist and Chief Investigator for PrevenTRON · Dementia · thecareruk.com · 7 Sept 2026 · Read the article
“For decades, research has focused on treating Alzheimer's disease after symptoms appear. PrevenTRON addresses a different question: whether we can act earlier, before symptoms begin. Through research and trials like PrevenTRON, we are very excited for the potential to help millions of people affected by Alzheimer's disease.”
psychiatry consultant at the University of Surrey · Dementia · pharmaphorum.com · 7 Sept 2026 · Read the article
“I'm not saying this trial is magic. It's an investigational medicine. We need to wait and see: will it work or not?”
Prof, consultant psychiatrist and chief investigator for the trial · Dementia · lbc.co.uk · 6 Sept 2026 · Read the article
“We are very excited for the potential to help millions of people affected by Alzheimer's disease.”
consultant psychiatrist and chief investigator for the trial · Dementia · express.co.uk · 5 Sept 2026 · Read the article
“The trial "addresses a different question, whether we can act earlier, before symptoms begin". "We are very excited for the potential to help millions of people affected by Alzheimer's disease."”
consultant psychiatrist and chief investigator for the trial · Dementia · bbc.co.uk · 5 Sept 2026 · Read the article
“For decades, research has focused on treating Alzheimer's disease after symptoms appear. PrevenTRON addresses a different question, whether we can act earlier, before symptoms begin.”
Professor, chief investigator for PrevenTRON in Europe, Surrey and Borders Partnership NHS Foundation Trust · Dementia · mirror.co.uk · 5 Sept 2026 · Read the article
“For decades, research has focused on treating Alzheimer's disease after symptoms appear. PrevenTRON addresses a different question, whether we can act earlier, before symptoms begin.”
consultant psychiatrist and chief investigator for the PrevenTRON trial · Dementia · theguardian.com · 5 Sept 2026 · Read the article
“For decades, research has focused on treating Alzheimer's disease after symptoms appear. PrevenTRON addresses a different question, whether we can act earlier, before symptoms begin.”
Professor; chief investigator for PrevenTRON in Europe, Surrey and Borders Partnership NHS Foundation Trust · Dementia · aol.co.uk · 5 Sept 2026 · Read the article
“I'm not saying this trial is magic. It's an investigational medicine. We need to wait and see: will it work or not?”
Professor; chief investigator for the PrevenTron trial · Dementia · independent.co.uk · 5 Sept 2026 · Read the article
“For decades, research has focused on treating Alzheimer's disease after symptoms appear. PrevenTRON addresses a different question, whether we can act earlier, before symptoms begin.”
Prof, consultant psychiatrist and chief investigator for the PrevenTRON trial · Dementia · aol.co.uk · 5 Sept 2026 · Read the article
“We are very excited for the potential to help millions of people affected by Alzheimer's disease.”
Prof, consultant psychiatrist and chief investigator for the trial · Dementia · aol.co.uk · 5 Sept 2026 · Read the article
“For decades, research has focused on treating Alzheimer's disease after symptoms appear. PrevenTron addresses a different question – whether we can act earlier, before symptoms begin.”
Chief investigator for the PrevenTron trial · Dementia · telegraph.co.uk · 4 Sept 2026 · Read the article
“For decades, research has focused on treating Alzheimer's disease after symptoms appear. PrevenTron addresses a different question - whether we can act earlier, before symptoms begin.”
Professor; chief investigator for the PrevenTron study and consultant at Surrey and Borders NHS Foundation Trust · Dementia · aol.co.uk · 4 Sept 2026 · Read the article
“For decades, research has focused on treating Alzheimer's disease after symptoms appear. PrevenTron addresses a different question -- whether we can act earlier, before symptoms begin.”
Professor; chief investigator for PrevenTron and consultant at Surrey and Borders NHS Foundation Trust · Dementia · express.co.uk · 4 Sept 2026 · Read the article
“research had "for decades" focused on treating Alzheimer's after symptoms appeared. The trial "addresses a different question, whether we can act earlier, before symptoms begin"”
consultant psychiatrist and chief investigator for the trial · Dementia · yahoo.com · Read the article

Related media coverage

Recent UK press coverage of their topics, not necessarily citing them directly.

06  Sources

References for this biography

  1. Professor Ramin Nilforooshan : Surrey and Borders Partnership NHS Foundation Trust. Current roles at SABP and the University of Surrey, R&D director, CRN dementia lead, and his trial investigator experience
  2. Surrey and Borders leads European Alzheimer's prevention trial. Chief Investigator for PrevenTRON, the trial's aims, and SABP's first-in-Europe status
  3. Major trial of Roche Alzheimer's drug kicks off in Europe. Press coverage quoting him as PrevenTRON's chief investigator
  4. Middle-aged people with NO memory problems offered Alzheimer's drug in world first. Press quotes attributed to The Telegraph, including his caution that the trial is not 'magic'
  5. Dr Ramin Nilforooshan (Red and Yellow Care). Training on the Guy's and Maudsley rotation, SABP consultant since 2011, and honorary and research fellow posts
  6. Convenzis - Speakers - Profile. Clinical lead for the award-winning TIHM NHS Test Bed, and his research interest in Alzheimer's biomarkers
  7. Study that uses AI to help people with dementia stay well at home scoops award. The TIHM for dementia study, led by the University of Surrey and SABP, won an HSJ Award
  8. New NHS home monitoring service launched to improve care for patients with dementia. Chief Investigator for the Minder study and the MinderCare service
  9. Dr Ramin Nilforooshan - University of Surrey. University of Surrey staff page and TIHM publications
  10. Contact us : Surrey and Borders Partnership NHS Foundation Trust. Trust Headquarters address: 18 Mole Business Park, Randalls Road, Leatherhead, KT22 7AD

07  Contact & links

Staff page
sabp.nhs.uk/our-services/professionals/consultant-search-directory/professor-Nilforooshan
Staff page
surrey.ac.uk/people/ramin-nilforooshan

Organisational contact points only, each taken from a page the organisation publishes itself. No personal or direct contact details are held or shown.

Doctors, nurses, allied health professionals and other registered clinicians quoted in a clinical capacity. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 13 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.